July 2025 - Corcept Therapeutics

Characterization of Individuals With Difficult-to-Control Type 2 Diabetes and Post-Dexamethasone Suppression Test Cortisol Values <1.2, 1.2–1.8, and >1.8 μg/dL: Findings From the CATALYST Part 1 Study

July 14, 2025

Auchus et al. • 2025 • ENDO 2025

The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension

July 14, 2025

Einhorn et al. • 2025 • ENDO 2025

Effects of Relacorilant on Body Weight and Body Composition in Patients With Endogenous Hypercortisolism in the Phase 3 GRACE and GRADIENT Studies

July 13, 2025

Hamidi et al. • 2025 • ENDO 2025

Efficacy and Safety of Relacorilant in Individuals With Adrenal Hypercortisolism: Results From the Phase 3 GRACE and GRADIENT Studies

July 13, 2025

Badiu et al. • 2025 • ENDO 2025

Effects of Relacorilant on Pituitary Tumor Volume in Patients With Cushing Disease: Results From the Phase 3 GRACE Study

July 10, 2025

Dobri et al. • 2025 • International Pituitary Congress